Drugs / Ethyl-eicosapentanoic acid
Ethyl-eicosapentanoic acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00096798 | Sep 2001 → Aug 2007 | depressive disorder | National Center for Complementary and Integrative Health (NCCIH) | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ethyl-eicosapentanoic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00096798 ↗ |
| Known as | EPA-E | “OBJECTIVE: To examine the efficacy and tolerability of ethyl-eicosapentaenoate (EPA-E) monotherapy for major depressive disorder (MDD).” PMID 19709502 ↗ Aug 2009 |
| Known as | ethyl-EPA | “Ethyl-eicosapentanoic acid (ethyl-EPA)” NCT00096798 ↗ |
| Modality | Small molecule | “ethyl-EPA, an omega-3 fatty acid, in treating depression.” NCT00096798 ↗ |
| Route | Oral | “Participants will be randomly assigned to receive either ethyl EPA-containing pills or placebo daily for 8 weeks.” NCT00096798 ↗ |